KR101293032B1 - Pharmaceutical composition for treating or preventing obesity comprising sea tangle and sodium butyrate as effective component - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for treating or preventing obesity and a food for preventing or improving obesity, containing kelp and sodium butyrate solution or powder as an active ingredient.

Description

Pharmaceutical composition for treating or preventing obesity comprising sea tangle and sodium butyrate as effective component

The present invention relates to a pharmaceutical composition for treating or preventing obesity and a food for preventing or improving obesity, containing kelp and sodium butyrate solution or powder as an active ingredient.

Seaweeds, including kelp, contain a lot of carbohydrates, mainly polysaccharides, and have a very low digestion rate due to digestive enzymes present in the human small intestine.However, carbohydrates in seaweeds in the large intestine have very high functionalities unlike the fiber contained in general vegetables. It is known. In other words, the effect of dietary fiber of seaweeds on the human body to facilitate the activity of the intestine, the release of heavy metals, the prevention of cholesterol deposition in the blood vessels, and the recent research findings that seaweed dietary fiber has anticancer action.

A recent study on kelp dietary fiber among seaweeds showed that 32.8% of soluble dietary fiber has high physiological activity in the human body, 17.9% of water-insoluble dietary fiber and 50.2% of total dietary fiber are the highest dietary fiber among plants and seaweeds. Has content. It is known that the dietary fiber of seaweeds is effective in obesity by satiating the gastrointestinal tract and interfering with digestion and absorption of other nutrients. However, in order to obtain an appropriate obesity inhibitory effect, a large amount of dietary fiber or an actual obesity inhibitory effect is insignificant. There are many cases.

Recently, with the improvement of living standards due to the modernization of the economy, a new dietary culture, in which fat and sugar intake is increased and fiber intake is reduced, especially eating out, has become a preference for high protein-oriented diets. The reality is that the obese population is rapidly increasing due to the few lifestyles of modern people. As the consumption of high-calorie foods increases and fiber intake decreases, obesity, especially abdominal obesity, is becoming a serious social problem. Obesity refers to a state in which fat tissue is excessively increased, and weight gain due to obesity is mostly due to an increase in fat.

Obesity is a problem that obesity itself causes a lot of constipation, indigestion, gastrointestinal disorders due to the pressure of the abdomen by the fat tissue, as well as the risk factors of many adult diseases. Obesity is known to cause all kinds of complications such as cancer, arteriosclerosis, heart disease, high blood pressure, diabetes and other complications, and in 1996, the World Health Organization (WHO) warned that obesity is a disease that needs treatment. A study of 750,000 people reported a 1.9-fold increase in mortality in men and women over 40% above average body weight compared to those of normal weight.

Obesity is a state in which excess fat is accumulated in the body, and the cause of fat accumulation in the body is excessive intake of sugar (carbohydrate) or excess intake of fat. The mechanism of reaching obesity is that by over-ingesting the sugars, the sugars in the food are digested and become monosaccharides and absorbed into the body through the small intestine.Increase the blood sugar and insulin secreted by the stimulus acts on fat cells to release the monosaccharides in the blood. Fat cells are taken in and converted into fat. In addition, fat (triglyceride), which is the highest calorie among food ingredients, is broken down by pancreatic lipase and absorbed through the small intestine, resulting in an increase in stored calories due to excess calories. That is, obesity is caused by excess fat intake.

Appetite suppressants, heat generators, and diuretics are currently used to treat obesity, and the most commonly used anti-obesity agents form appetite suppressants in the US for $ 10 million a year. However, appetite suppressants for the treatment of obesity have side effects such as increased blood pressure, dependence, diarrhea, constipation, insomnia, and anxiety. Therefore, interest in the use of various food materials whose safety and physiological functions have been proven for many years to suppress obesity is increasing. have. Currently, products containing dietary fiber, herbal medicines and various food ingredients have been developed as a health food for obese people.However, if you reduce the amount of meals and consume these products, normal life is difficult due to side effects due to lack of various nutrients. It is known to quickly become obese again

Korean Patent No. 0562467 discloses an anti-obesity agent, and Korean Laid-Open Patent No. 2004-0095949 discloses a composition for inhibiting obesity including plant leaves, but contains kelp and sodium butyrate of the present invention as an active ingredient. It is different from the composition for inhibiting obesity.

The present invention has been made by the above-described needs, and an object of the present invention is to provide a composition capable of enhancing the effect of inhibiting obesity by containing kelp and sodium butyrate solution or powder as an active ingredient.

In order to solve the above problems, the present invention provides a pharmaceutical composition for treating or preventing obesity containing kelp and sodium butyrate solution or powder as an active ingredient.

In addition, the present invention provides a food for preventing or improving obesity containing kelp and sodium butyrate solution or powder as an active ingredient.

The present invention is a composition containing kelp and sodium butyrate solution or powder as an active ingredient to enhance the obesity inhibitory effect compared to ingesting kelp alone to be a very useful invention for the pharmaceutical and food industry for inhibiting obesity will be.

In order to achieve the object of the present invention, the present invention provides a pharmaceutical composition for treating or preventing obesity containing kelp and sodium butyrate solution or powder as an active ingredient.

In the pharmaceutical composition of the present invention, the kelp may be preferably spray dried kelp for 7-9 hours at 70 ~ 90 ℃ after grinding, more preferably spray dried kelp for 8 hours at 80 ℃ after grinding May be, but is not limited thereto.

In the pharmaceutical composition of the present invention, the sodium butyrate solution may be preferably a solution prepared by adding 0.02 to 0.06% by volume of sodium butyrate to distilled water, and more preferably, by adding 0.04% by volume of sodium butyrate to distilled water. It may be a prepared solution, but is not limited thereto.

The composition of the present invention may comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.

The pharmaceutical dosage forms of the compositions of the present invention may also be used in the form of their pharmaceutically acceptable salts and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable set.

The composition according to the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., oral preparations, suppositories and sterilized injection solutions according to a conventional method have. Carriers, excipients and diluents that may be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl And various compounds or mixtures including cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose ), Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The preferred dosage of the composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the composition of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably at 0.001 to 100 mg / kg. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.

The composition of the present invention may be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.

The present invention also provides a food for preventing or improving obesity containing kelp and sodium butyrate solution or powder as an active ingredient.

The food is not particularly limited as long as it can be ingested to prevent or improve obesity.

When the kelp and sodium butyrate solutions or powders of the present invention are used as food additives, the kelp and sodium butyrate solutions or powders may be added as such or used together with other food or food ingredients, and may be suitably used according to conventional methods. Can be. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment). In general, the tangle and sodium butyrate solution or powder of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less based on the raw material in the manufacture of food or beverage. However, in the case of long-term consumption intended for health and hygiene purposes or for health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range .

There is no particular limitation on the kind of the food. Examples of foods to which the kelp and sodium butyrate solution or powder may be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, including ice cream, various soups, Drinks, teas, drinks, alcoholic beverages and vitamin complexes and the like, and includes all of the health food in the conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like.

In addition to the above, the health beverage composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, Alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the health beverage composition of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, embodiments of the present invention will be described in detail. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.

1. Animal experiments to analyze the obesity inhibitory effect of kelp

(1) public animals

48 48-week-old female rats

(2) Test feed and test design

Animal experiments were carried out with 48 rats of four-week-old female rats (SAMTAKO Bio Korea) for 4 days, with 3 treatments, 4 repetitions, and 4 repetitions, including control, kelp and kelp + sodium butyrate treatment (SAMTAKO Bio Korea). Animal experiments were carried out after 28 days. During the breeding period, the test feed was fed in the form of Control (Basic diet, Basal diet), BDST (Basic diet + 10% dried kelp), BDSTB (Basic diet + 10% dried kelp + 0.04% Sodium butyrate).

Classification of Animal Experimental Groups for Analyzing Obesity Inhibitory Effects Items Treatment ^a system
Control BDST BDSTB repeat 4 4 4 Marie / Repeat 4 4 4 Number of birds per treatment 16 16 16 48 Basic feed ○ Basic feed + 10% dried kelp ○ Basic Feed + 10% Dried Kelp +
0.04% Sodium butyrate ○ Specification period (days) 28

^a Control (Basal diet), BDST (Basic diet + 10% dry kelp), BDSTB (Basic diet + 10% dry kelp + 0.04% Sodium butyrate)

Feed preparation for each treatment group was ground with the kelp additive for each treatment, mixed with purified water, and then spray dried at 80 ° C. for about 8 hours. The sodium butyrate treatment of the BDSTB treatment group was orally administered by adding 0.04% sodium butyrate to 1 ml of sterile distilled water. In addition, in order to perform the animal experiments under the same conditions, all treatments except the BDSTB treatment was also administered orally 1 ml of sterile distilled water. The environment of experimental animal breeding room was maintained at a temperature of 22 ± 2 ℃ and a relative humidity of 65 ± 5%, and the contrast period was adjusted to a 12 hour period (lighting 7: 00 ~ 19: 00).

Basic Diet Ingredients and Mixing Ratio Ingredients
Basal diet g kcal Casein 200 800 Corn starch 150 600 Sucrose 500 2000 Cellulose 50 - Corn oil 50 450 Mineral mixture 35 - Vitamin mixture 10 40 DL-methionine 3 12 Choline bitartrate 2 - Total 1000 3902

Chemical Composition of the Basal Diet Chemical composition content(%) Crude protein 21.33 Crude fat 5.26 Crude fiber 5.32 Crude ash 6.55 Moisture 9.45 Calcium 0.88 Phosphorus 0.72

(3) Survey items

Weight gain: Weight gains measured at weekly intervals from start to end of the test (total weight gain and daily weight gain)

Feed intake: measure the remaining feed in each iteration just before daily feed

Feed efficiency: calculated based on feed intake and weight gain

Example  1: Effect of Kelp Powder Supplementation on Growth Efficiency

In order to investigate the effects of kelp powder supplementation on the growth efficiency of rats, the body weight was measured four times a week from the start of the test to the end of the test. Based on this, it was expressed by weight gain, total feed intake and feed efficiency by period (Tables 4 and 5).

Body weight gain was significantly different between control (C) and treatment groups from the first week after the start of the test, especially in the BDSTB group with butyrate added from 3 weeks. Daily weight gain was 3.12 g in control, kelp and kelp + butyrate, respectively. 2.29 g, 2.15 g showed a tendency to decrease in the treatments compared to the control, especially the lowest daily gain in kelp + butyrate added (BDSTB). Is shown (Table 4).

Effects of Kelp Powder Supplementation on Weight Gain by Breeding Period Body weight (g)
Treatments ^a C BDST BDSTB Initial body weight (g) 136.15 137.13 138.33 1 week 169.31 149.39 152.98 2 week 188.48 171.69 174.91 3 week 208.07 182.67 177.83 4 week 223.43 201.28 198.53 Body weight gain (g) 87.28 64.14 60.20 Average daily gain (g) 3.12 2.29 2.15

^a C (Basal diet), BDST (Basic diet + 10% dry kelp), BDSTB (Basic diet + 10% dry kelp + 0.04% Sodium butyrate)

Feed intake was 62.64 g, 55.59 g and 57.94 g in control, kelp and kelp + butyrate, respectively, indicating that the addition of kelp decreased feed intake. The feed efficiency of dividing feed intake by weight gain was 4.98, 4.12 and 3.71 in control, kelp and kelp + butyrate, respectively, and the feed intake was lowered by adding kelp, especially in kelp + butyrate. (Table 5).

The decrease in feed efficiency by lowering the intake and daily weight increase of kelp is because the dietary fiber content of kelp is 50.2%, which is the highest dietary fiber content among plants and algae, and the fiber contained in the gastrointestinal tract It gives you a feeling of satiety and interferes with the digestion and absorption of other nutrients you eat. Therefore, the dietary fiber of kelp seems to be directly related to the obesity inhibitory effect. Could.

Feeding amount and feed efficiency of feed with kelp powder Feed Intake (g)
Treatments ^a C BDST BDSTB 1 week 439.43 346.53 385.20 2 week 405.35 376.75 382.05 3 week 430.00 393.00 418.60 4 week 479.05 440.38 436.35 Total feed intake (g) 1753.83 1556.65 1622.20 Average daily feed intake (g) 62.64 55.59 57.94 Feed conversion ratio 4.98 4.12 3.71

^a C (Basal diet), BDST (Basic diet + 10% dry kelp), BDSTB (Basic diet + 10% dry kelp + 0.04% Sodium butyrate)

Claims (5)

Pharmacy for the treatment or prevention of obesity, containing sodium butyrate solution prepared by adding 0.02-0.06% by volume of sodium butyrate to spray dried kelp and distilled water at 70-90 ° C. after grinding Composition. delete delete Food for preventing or improving obesity containing sodium butyrate solution prepared by adding 0.02 to 0.06% by volume of sodium butyrate to spray dried kelp and distilled water at 70-90 ° C. after grinding . The method of claim 4, wherein the food is meat, cereals, beverages, chocolate, breads, snacks, confectionery, pizza, jelly, noodles, gums, ice creams, alcoholic beverages, alcohol, vitamin complexes or health supplements, characterized in that Food for preventing or improving obesity.